Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Comprehensive

Begone Floaters!

The tide is turning for patients with vision-degrading vitreopathy.

Landmark paper: J Sebag et al., “Long-Term Safety and Efficacy of Limited Vitrectomy for Vision Degrading Vitreopathy Resulting from Vitreous Floaters”, Ophthalmology Retina, 9, 881–887 (2018). DOI: e201803011

This study, published in September 2018, looked at outcomes of patients undergoing vitrectomy for vitreous opacities, also known as vitreous floaters (1). Vitreous opacities contribute to the disease entity of vision-degrading vitreopathy, which can lower visual acuity (VA) and degrade contrast sensitivity function (CSF). Vitrectomy for floaters has remained controversial, and much debate has occurred about the appropriateness of vitreoretinal surgery for patients with good VA but bothersome floaters; however, with the widespread adoption of micro incisional vitrectomy surgery (MIVS), efficient and safe surgical approaches are available that should be considered. Prior to this study, long-term results in a large series with objective quantitative outcome measures were lacking.

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

David Almeida

David Almeida holds an MD from Queen’s University in Kingston, Ontario, an MBA from George Washington University School of Business in Washington, D.C., and a PhD in Pharmaceutical Drug Research from the University of Szeged. A 2017 The Ophthalmologist Power List Rising Star, he’s not only a practicing surgeon with Vitreoretinal Surgery, PA in Minneapolis- St. Paul, Minnesota, but also cofounder of the pharmaceutical company Citrus Therapeutics. His best-selling book, Decision Diagnosis: Seven Antidotes to Decision Procrastination, blends the spheres of medicine, science, business, and leadership to present new concepts and strategies for successful decision making.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register